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Abstract
Despite tremendous progress in our understanding of human immunodeficiency virus (HIV)
natural history and advances in HIV treatment, there is neither an approved vaccine nor a
cure for infection. Here, we describe the development and characterization of a novel repli-
cating vaccine vector utilizing Cytomegalovirus (CMV) and a TLR5 adjuvant. After partial
truncation of the central, immunodominant hypervariable domain, flagellin (fliC) from Salmo-
nella was cloned downstream of a codon optimized gag gene from simian immunodefi-
ciency virus (SIV) and transiently expressed in telomerized rhesus fibroblast (TeloRF) cells
in culture. Lysates generated from these transfected cells induced the tumor necrosis factor
alpha (TNF-α), in a mouse macrophage cell line, in a TLR5-dependent manner. The Gag/
FliC expression construct was cloned into a bacterial artificial chromosome encoding the
rhesus CMV (RhCMV) genome, and infectious RhCMV was generated following transfec-
tion of TeloRF cells. This virus stably expressed an SIV Gag/FliC fusion protein through four
serial passages. Lysates generated from infected cells induced TNF-α in a TLR5-depen-
dent manner. Western blot analysis of infected cell lysates verified expression of a Gag/FliC
fusion protein using a SIV p27 capsid monoclonal antibody. Lastly, rhesus macaques inocu-
lated with this novel RhCMV virus demonstrated increased inflammatory responses at the
site of inoculation seven days post-infection when compared to the parental RhCMV. These
results demonstrate that an artificially constructed replicating RhCMV expressing an SIV
Gag/FliC fusion protein is capable of activating TLR5 in a macrophage cell line in vitro and
induction of an altered inflammatory response in vivo. Ongoing animals studies are aimed
at determining vaccine efficacy, including subsequent challenge with pathogenic SIV.
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Introduction
Thirty years of research has revealed major insights into the human immunodeficiency virus
(HIV-1) replication cycle, pathogenesis, and immune responses; however, there is neither an
approved vaccine nor a broadly applicable cure for HIV-1 infection. Although combination
antiretroviral therapy (cART) [1] is capable of controlling HIV-1 infection, low-level viremia
persists [2] and virus in plasma rebounds if cART is interrupted [3]. HIV-1 infected people
must also remain on cART indefinitely to prevent further destruction of their immune systems
and progression to acquired immune deficiency syndrome (AIDS). Chronic, non-AIDS associ-
ated diseases in people undergoing long-term treatment demonstrate that cART does not
completely restore health and emphasize the need for a vaccine or a cure (reviewed in [4, 5]).
Results from the RV144 vaccine clinical trial suggest for the first time that a vaccine to pre-
vent the acquisition of HIV-1 might be possible. The RV144 vaccine regimen consisted of four
serial vaccinations with a canarypox vector expressing the HIV-1 Envelope glycoprotein
(gp120; ALVAC-HIV) combined with two serial vaccinations with recombinant HIV-1 gp120
(AIDSVAX B/E) [6]. Modified intention-to-treat analysis suggested a 31% vaccine efficacy in
prevention of HIV-1 acquisition in the vaccine group versus the placebo control group for the
three-year study duration [6]. However, a follow-up study revealed a cumulative vaccine effi-
cacy in prevention of HIV-1 infection of 61% through the first 12 months after immunization
that declined over time [7]. While the decline in vaccine efficacy over time requires further
investigation to fully understand the mechanism, additional or prolonged boosting of the initial
immune response might be required to improve long-term vaccine efficacy. It is important to
note that while the RV144 vaccine regimen reduced the risk of HIV-1 infection, it did not
reduce viral load or protect from loss of CD4+ T cells in those that became infected [6].
A unique vaccination strategy utilizing recombinant viral vectors takes advantage of the per-
sistent nature of the betaherpesvirus, cytomegalovirus (CMV). Using the well-defined rhesus
macaque (Macaca mulatta) nonhuman primate model of AIDS, recombinant rhesus CMVs
(RhCMV) have been constructed that express the simian immunodeficiency virus (SIV) pro-
teins: Gag, Env, and Rev/Tat/Nef (and Pol) [8, 9]. These RhCMV-vectored SIV vaccines
induced effector T cell immune responses that resulted in long-term control of SIV infection in
50% of the mucosally-challenged animals [9], with some animals apparently clearing the infec-
tion [10]. Prolonged antigenic stimulation due to the persistent nature of the RhCMV vector
combined with an unconventional CD8 T-cell response suggest novel, unprecedented protec-
tive mechanisms that could confer long-term control and clearance of virulent SIV infection
[8, 11]. Whether these responses can be enhanced to protect a greater percentage of the chal-
lenged animals is key to further development of this promising strategy.
One method of enhancing immunogenicity of a particular antigen is through the use of an
adjuvant. Pattern recognition receptor agonists, including the Toll-like receptor 5 (TLR5) ago-
nist, Flagellin (FliC), have been tested as vaccine adjuvants that manipulate the innate immune
response and thereby strengthen adaptive immune responses to particular antigens (reviewed
in [12, 13]). Recent studies have demonstrated enhanced immunogenicity of recombinant anti-
gens delivered either concomitantly or fused with FliC in mice and nonhuman primate animal
models [14–20]. Stimulation of the TLR5 receptor by FliC resulted in the induction of a proin-
flammatory response and the direct activation of TLR5-expressing CD11c+ dendritic cells [12,
21]. FliC may also directly activate CD4+ and CD8+ lymphocytes (reviewed in [12]).
Here, we describe the construction of a recombinant RhCMV that expresses a SIV Gag-Sal-
monella FliC fusion protein in which the region of FliC containing immunodominant epitopes
has been deleted. This virus is subsequently characterized for expression of an SIV Gag FliC
fusion protein with TLR5 ligand-specific bioactivity.
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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Results
FliC hypervariable region mutants stimulate TNF-α Expression in vitro
The two TLR5 binding domains of FliC are located within the well-conserved N and C termini
(amino acid residues 79–117 and 408–439, respectively) [22]. The central region consists of an
immunodominant hypervariable (HV) domain (residues 185–306) that is targeted by the adap-
tive immune system [22]. The HV domain of FliC was partially truncated to prevent an adap-
tive immune response to the adjuvant portion of the vaccine and to reduce the size of the total
fusion open reading frame for more efficient cloning into the RhCMV bacterial artificial chro-
mosome (BAC) [23]. Two separate Salmonella enterica serovar Enteritidis fliC truncations
were constructed by deleting the nucleotides encoding amino acid residues 196–378
(fliCΔ196–378), as previously described [14], in addition to a novel second, larger deletion of
amino acid residues 141–398 (fliCΔ141–398). These genes, along with wild-type fliC, were
cloned into the eukaryotic expression vector, pORI, under control of the EF1 alpha promoter,
generating the three plasmids: pORIfliCΔ196–378, pORIfliCΔ141–398 and pORIfliC.
The TLR5-positive mouse macrophage cell line (RAW424) and its parental TLR5-negative
cell line (RAW264.7) [14] were treated with recombinant FliC to measure TLR5-specific bioac-
tivity. Cell culture supernatants were collected from the RAW cells and analyzed by enzyme-
linked immunosorbant assay (ELISA) for proinflammatory cytokine, tumor necrosis factor-α
(TNF-α). Treatment of RAW424 cells with recombinant FliC confirmed cell line secretion of
TNF-α by ELISA, while the absence of TNF-α in FliC-treated RAW264.7 cell supernatants
confirmed that the RAW424 cell response was TLR5 specific (Fig 1A).
To determine the TLR5-specific bioactivity of the FliC truncations, plasmids pORI-
fliCΔ196–378, pORIfliCΔ141–398 and pORIfliC were transfected into telomerized rhesus
fibroblast (TeloRF) cells and freeze-thaw lysates were generated. RAW424 cells exposed to
these lysates demonstrated that all three plasmids induced TNF-α in a TLR5 dependent man-
ner (Fig 1B). Plasmid pORIfliCΔ196–378 stimulated TNF-α levels similar to those observed
with wild-type flagellin (pORIfliC) (Fig 1B). However, pORIfliCΔ141–398 stimulated signifi-
cantly lower concentrations of TNF-α compared to those induced by plasmids pORIfliC and
pORIfliCΔ196–378 based on a one-way ANOVA with Tukey’s multiple comparisons test (Fig
1B; P value< 0.0001). Plasmid pORIfliCΔ196–378 was selected for construction of a SIV Gag
FliC fusion protein as a vaccine antigen based on these results.
SIV Gag-FliC fusion proteins stimulate TNF-α in vitro
Previous studies have demonstrated that antigens directly fused to FliC induce superior
immune responses compared to delivery of vaccine antigen and FliC as separate proteins [14,
21]. Plasmids encoding SIV Gag-FliC fusion proteins were constructed and assessed for induc-
tion of TNF-α. SIV gag was cloned into the expression vector, pORI, and two separate expres-
sion plasmids were constructed by inserting either wild type fliC or fliCΔ196–378 downstream
of the SIV gag gene (full length), generating pORIgagfliC and pORIgagfliCΔ196–378 (Fig 2). A
single AgeI restriction endonuclease recognition site (REase) separated the SIV gag and fliC
genes. The resulting fusion genes encoded a single Kozak sequence and a single start codon
located at the 5’ end of SIV gag, and a single transcription termination signal located at the 3’
end of fliC or fliCΔ196–378. Cellular lysates were generated from TeloRF cells transiently trans-
fected with SIV gag/fliC expression plasmids to assess for TLR5 stimulating activity. RAW424
(TLR5+) and RAW264.7 (TLR5-) cells were treated with the lysates, and cell culture superna-
tants were analyzed for concentrations of TNF-α by ELISA. Treatment of RAW cells with a
3-log10 serial dilution of recombinant FliC demonstrated the linear range of the assay while the
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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lack of a response in RAW264.7 cells treated with recombinant FliC demonstrated that the
observed TNF-α stimulation in treated RAW424 cells was dependent upon TLR5 (Fig 3A).
RAW264.7 cells treated with lysates from TeloRF cells transfected with any of the FliC encod-
ing plasmids did not result in induction of TNF-α (Fig 3B). In contrast, RAW424 cells treated
with the same TeloRF lysates exhibited significant induction of TNF-α over mock-treated
Fig 1. Recombinant FliC and truncated FliC expressed from plasmid pORI induce TNF-α in a
TLR5-dependent manner. TNF-α ELISA of cell culture supernatants collected from TLR5-positive RAW424
(Blue) or its parental TLR5-negative RAW264.7 (Red) mouse macrophage cells. (A) RAW cells were treated
with increasing concentrations of recombinant FliC. (B) Telomerized rhesus fibroblast cells were transiently
transfected with plasmids containing full-length FliC (pORIfliC) or partially truncated FliCs (pORIfliCΔ196–
378 or pORIfliCΔ141–398) and freeze thaw lysates were generated. Cell culture supernatants harvested
from RAW cells treated with these lysates were assayed by an ELISA that measures TNF-α production. An
average of two independent experiments and means with standard deviation are presented.
doi:10.1371/journal.pone.0155629.g001
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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RAW424 cells (Fig 3C). A one-way ANOVA with Tukey’s multiple comparisons test deter-
mined that the observed levels of TNF-α induced by each FliC-encoding vector was signifi-
cantly different from the RAW424 cells treated with lysates from mock-transfected TeloRF
cells (P value< 0.0001). Together, these data demonstrated that SIV Gag-FliC and SIV Gag-
FliCΔ196–378 fusion proteins expressed from transfected TeloRF cells induce TNF-α in
RAW424 cells in a TLR5-dependent manner.
RhCMV encoding an SIV Gag-FliCΔ196–378 fusion protein stimulates
TNF-α in vitro
To generate RhCMV expressing an SIV Gag-FliC fusion protein, the SIV gagfliCΔ196–378
fusion gene was cloned from pORIgagfliCΔ196–378 into a previously described BAC [23]
encoding an infectious RhCMV genome (RhCMV 68–1) using Red/ET and Flp-mediated
recombination, generating RhCMVgagfliCΔ196–378 BAC. The gagfliCΔ196–378 insertion site
was located in the intergenic region between rh213 and rh214 genes of RhCMV-loxP(r) (Fig 4)
[8, 23]. TeloRF cells transfected with the RhCMVgagfliCΔ196–378 BAC were maintained until
the culture exhibited nearly complete cytopathic effect. Cell culture supernatant was collected,
Fig 2. Flow Chart depicting construction of vectors encoding SIV gag Salmonella fliC fusion proteins. Salmonella fliCwas
cloned in frame downstream of the SIV gag gene. The final fusion construct encoded a single Kozak sequence and translation start
codon at the 5’ end, and a single stop codon at the 3’ end. A single AgeI restriction endonuclease recognition site separated the two
proteins.
doi:10.1371/journal.pone.0155629.g002
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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designated passage one (P1) virus and used to infect fresh TeloRF cells through four serial pas-
sages. Cell culture lysates were generated from each viral passage and analyzed using
RAW264.7 cells (Fig 5A) and RAW424 cells (Fig 5B) for induction of TNF-α by ELISA. The
results demonstrated that RhCMVgagfliCΔ196–378 induced production of TNF-α in a
TLR5-dependent manner and that this activation of TLR5 was stable through all four serial
passages.
To determine the kinetics of RhCMVgagfliCΔ196–378 gene expression, cell lysates prepared
from infected TeloRF cells were assayed for induction of TNF-α on RAW cells as described
Fig 3. Gag-FliC and GagFliCΔ196–378 fusion proteins induce TNF-α in a TLR5-dependent manner. TNF-α ELISA analysis of cell culture
supernatants collected from TLR5-positive RAW424 cells (Blue) or TLR5-negative RAW264.7 cells (Red) are shown. (A) Linear regression analysis of
RAW cells treated with recombinant FliC. (B) RAW264.7 cells or (C) RAW424 cells treated with freeze/thaw lysates collected from TeloRF cells
transiently transfected with the expression vectors pORIfliC, pORIfliCΔ196–378, pORIgagfliC or pORIgagfliCΔ196–378. Data represent the average of
two independent experiments with means and standard deviations shown by error bars.
doi:10.1371/journal.pone.0155629.g003
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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above. Treatment of RAW cells with recombinant FliC determined the linear range of the assay
(Fig 6A). Accordingly, treatment of RAW264.7 cells with the RhCMVgagfliCΔ196-
378-infected TeloRF cell lysates did not induce TNF-α (Fig 6B) while treatment of RAW424
cells with the same lysates demonstrated increasing TNF-α induction over time, with peak
expression levels occurring with the lysates collected at 48 hours post-infection (Fig 6C). The
results demonstrated maximum GagFliCΔ196–378 expression from recombinant RhCMVgag-
fliCΔ196–378 within 48 hours of infection in TeloRF cells with gene expression stable for at
least 96 hours post-infection (Fig 6C). The absence of TNF-α induction in RAW cells treated
with lysates from TeloRF cells infected with either RhCMV or RhCMV expressing SIV Gag
alone (RhCMVgag) confirmed that induction of TNF-α was specific to the gagfliCΔ196–378
insert.
RhCMV-expressed SIV Gag-FliCΔ196–378 fusion protein remains intact
in TeloRF cells
To confirm stability of the Gag-FliCΔ196–378 fusion protein expressed from RhCMVgag-
fliCΔ196–378, infected TeloRF cell lysates were assessed for expression of SIV Gag by Western
blot analysis. Cell lysates from TeloRF cells infected with RhCMV (Fig 7A), RhCMVgag
Fig 4. RhCMVgagfliCΔ196–378 virus map. The SIV gag-Salmonella fliC fusion gene was cloned from the expression plasmid pORIgagfliCΔ196–378
into a BAC encoding the RhCMV 68–1 genome. The insertion site was in the intergenic region between Rh213 and Rh214 of the RhCMV genome. The
open arrow indicates the EF1-α promoter. The start and stop codons and the restriction endonuclease sites used in the cloning process are indicated
above the colored bars. The orange bar indicates SIV gag. The solid blue bars designate the conserved carboxyl and amino termini of fliC, containing the
TLR5 binding domains. The light blue bar with white dots designates the partially truncated fliC hypervariable domain.
doi:10.1371/journal.pone.0155629.g004
Fig 5. RhCMVgagfliCΔ196–378 serial passage in TeloRF cells. RAW264.7 cells (A) or RAW424 cells (B) were treated
with lysates from TeloRF cells infected with RhCMVgag (black bars) or RhCMVgagfliCΔ196–378 upon serial passage. Cell
culture supernatants were collected after four hours of treatment and analyzed for TNF-α by ELISA. Data represent means
with standard deviations.
doi:10.1371/journal.pone.0155629.g005
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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(Fig 7B), or RhCMVgagfliCΔ196–378 (Fig 7C) were collected over 96 hours post-infection in
denaturing sample buffer. Cell lysates (no virus) and all lysates generated from infected cells
contained a background protein of approximately 70 kD that reacted with the SIV Gag (p27)
monoclonal antibody (Lane 2 in Fig 7A–7C). TeloRF cells infected with RhCMV expressed no
other SIV Gag (p27) antibody-reactive proteins. Lysates from RhCMVgag-infected TeloRF
cells contained the expected 57 kD protein, equivalent to full-length SIV Gag polyprotein, and
an additional unknown protein at approximately 40 kD, both of which increased in concentra-
tion over the course of infection. RhCMVgagfliCΔ196-378-infected TeloRF cell lysates con-
tained the 57 kD SIV Gag protein, the unknown 40 kD protein, and another band at the
expected 93 kD weight of the SIV Gag-FliCΔ196–378 fusion protein (854 amino acids). All
three of these proteins (40 kD, 57 kD, and 93 kD) increased in concentration in the infected
Fig 6. RhCMV-encoded Gag-FliCΔ196–378 fusion protein expression kinetics. A) To determine the linear range of the TLR5 Biological
Assay, RAW cells were treated with recombinant FliC, and TNF-α in the supernatant was quantified by ELISA. The graph indicates linear
regression analysis.B and C) TeloRF cells were then infected with RhCMV, RhCMVgag, or RhCMVgagfliCΔ196–378 and cell lysates were
generated at the indicated times post-infection. The infected cell lysates were assessed for induction of TNF-α as described above on
RAW264.7 cells (B) or RAW424 cells (C).
doi:10.1371/journal.pone.0155629.g006
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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Fig 7. RhCMVgagfliCΔ196–378 expresses an SIV Gag-FliCΔ196–378 fusion protein.Western blot
analysis of samples collected at the indicated times post-infection from TeloRF cells infected with either (A)
RhCMV, (B) RhCMVgag, or (C) RhCMVgagfliCΔ196–378 were tested for reactivity with Gag p27 and actin
(loading control) monoclonal antibodies. BioRad Precision Plus Protein Dual Color Standards indicate
molecular weights (Lane 1). Lysates generated from TeloRF cells (No Virus; Lane 2) indicate background
reactivity with the p27 antibody. Lysates of tissue culture supernatant collected from CEMx174 cells infected
with SIVmac239 were used as positive controls for detection of SIV Gag (Lane 3).
doi:10.1371/journal.pone.0155629.g007
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cells over time, peaking in concentration at approximately 72 hours post-infection. These
results demonstrated that RhCMVgagfliCΔ196–378 in TeloRF cells expressed a fusion protein
that cross-reacted with an SIV Gag (p27) monoclonal antibody at the appropriate size for a
full-length SIV Gag-FliCΔ196–378 fusion protein.
RhCMV expressing SIV Gag-FliC fusion proteins induce an
inflammatory response in vivo
Through stimulation of the TLR5 receptor, FliC induces the production of the proinflamma-
tory cytokine TNF-α, resulting in the activation and recruitment of antigen presenting cells
(APC). For this reason, we hypothesized that skin biopsies collected from macaques after sub-
cutaneous (SC) inoculation with RhCMV expressing an SIV Gag-FliC fusion protein
(RhCMVgagfliCΔ196–378) would demonstrate increased inflammatory cell infiltrates at the
site of inoculation as compared to biopsies collected from macaques infected with the parental
strain of RhCMV or RhCMV expressing only SIV Gag (RhCMVgag). To test this hypothesis,
eight RhCMV seronegative macaques were inoculated SC with 1x104 plaque forming units
(pfu) of RhCMV68-1, RhCMVgag, or RhCMVgagfliCΔ196–378 and skin biopsies were col-
lected seven days post-infection based on a previous study revealing this time point to show
the optimum RhCMV expression in skin post SC infection [24]. Slides generated from the
biopsies were stained with hematoxylin and eosin (H&E), and scored for inflammatory cell
infiltrates (Fig 8A). Macaques from all three groups exhibited inflammatory responses at the
site of inoculation that were characteristic of infection with RhCMV. Although the difference
between groups was not statistically significant, macaques inoculated with RhCMVgag-
fliCΔ196–378 demonstrated increased inflammatory scores compared to macaques inoculated
with RhCMV and RhCMVgag.
While CMV generates robust immune responses that control viral replication and prevent
disease progression in immune competent hosts, there is evidence to suggest that these
immune responses do not protect from re-infection with CMV. To determine whether
RhCMV sero-positive macaques demonstrated the same trend towards increased inflamma-
tory cell infiltrates at the inoculation site, six RhCMV seropositive macaques were inoculated
with RhCMVgag and five RhCMV seropositive macaques were inoculated with RhCMVgag-
fliCΔ196–378. Slides generated from skin biopsies collected seven days post-inoculation were
stained by H&E and scored for inflammatory cell infiltrates (Fig 8B). These biopsies exhibited
a lower magnitude of inflammation overall compared to the biopsies collected from RhCMV
sero-negative macaques (Fig 8A). However, the trend towards increased inflammation in
RhCMVgagfliCΔ196–378 inoculated macaques observed in the sero-negative macaques was
also observed in these RhCMV sero-positive macaques. Together, these data suggest that
despite prior immune responses, RhCMVgagfliCΔ196–378 can induce pro-inflammatory
responses at the site of inoculation that are unique to this RhCMV-vectored virus.
Discussion
RhCMV vectors expressing lentiviral genes has demonstrated tremendous potential as a vac-
cine vector for HIV due to chronic antigenic stimulation and unique mechanisms of immune
presentation as revealed by the RhCMV68-1 variant [11]. Here, we have described the genera-
tion of a recombinant RhCMV, RhCMVgagfliCΔ196–378, which encodes a novel fusion pro-
tein consisting of a truncated FliC, a TLR5 agonist, and SIVmac239 Gag. Results demonstrated
that RhCMVgagfliCΔ196–378 is capable of stable expression of the SIV Gag-FliC fusion pro-
tein over multiple passages of virus as confirmed by western blot analysis and TLR5 bioactivity.
Furthermore, expression of this fusion protein in RhCMVgagfliCΔ196-378-infected cells
TLR5-Adjuvanted Cytomegalovirus Lentiviral Vaccine
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induces the pro-inflammatory cytokine TNF-α in a TLR5-dependent manner. Lastly,
RhCMVgagfliCΔ196–378 induces a higher magnitude of inflammatory cell infiltrates in associ-
ation with evidence of RhCMV expression and replication at the site of inoculation in rhesus
macaques.
Flagellin has been investigated as an adjuvant in a growing body of studies (reviewed in
[12]). While the majority of these studies utilize full-length FliC, FliCΔ196–378 encoding a par-
tial truncation of the HV domain has been utilized as one approach to prevent the induction of
an adaptive immune response to flagellin [14, 15]. The well-defined FliC TLR5-binding
domains remained intact with this truncation and as a consequence, the deletion did not signif-
icantly affect TLR5 bioactivity (Fig 1B). Interestingly, a larger FliC truncation (FliCΔ141–398)
Fig 8. Inflammatory responses to RhCMVgagfliCΔ196–378 in RhCMVmacaques. (A) Eight RhCMV
sero-negative macaques were inoculated with RhCMV, RhCMVgag, or RhCMVgagfliCΔ196–378 and skin
biopsies were collected seven days post-infection at the site of inoculation. (B) RhCMV sero-positive
macaques were infected with either RhCMVgag (six macaques) or RhCMVgagfliCΔ196–378 (five
macaques) and skin biopsies were collected at the site of inoculation seven days post-infection. Slides
generated from the skin biopsies were stained by H&E and scored for inflammatory cell infiltrates. Charts
indicate the observed inflammation with 0 (white) representing no observed inflammation, 1 (light blue)
representing mild inflammation, 2 (medium blue) representing moderate inflammation, and 3 (darkest blue)
representing severe inflammation.
doi:10.1371/journal.pone.0155629.g008
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demonstrated significantly reduced TLR5 bioactivity when compared to the FliCΔ196–378
truncation and wild-type FliC (Fig 1B). While the TLR5 binding domains within FliCΔ141–
398 were predicted to remain intact based on a previous report [22], a different report showed
that TLR5 binding utilized residues between 386–407 [25], which are affected by this 141–398
truncation. Due to a partial loss of TLR5 bioactivity, the FliCΔ141–398 truncation might prove
useful in future studies designed to modulate levels of proinflammatory responses.
In this study, FliC was fused to the carboxyl-terminus of SIV Gag. This orientation was
based upon previous studies and current literature (reviewed in [12]). Other orientations of
FliC fusion proteins have been described, including N-terminal, C-terminal, and insertion of
the antigen within the hypervariable domain of FliC [14, 15, 26]. While fusion proteins utiliz-
ing these various orientations have demonstrated efficacy, there is no current model to predict
a priori the optimal orientation. Factors involved in optimal gene expression and adjuvant
effects of FliC-antigen fusion proteins remain to be determined. It is possible that a stronger
adjuvant effect might be obtained with an alternate SIV Gag-FliC fusion protein orientation.
However, it is clear that the SIV Gag-FliC fusion protein described in this study induces TNF-
α in a TLR5-specific manner, regardless of whether the protein is expressed from a plasmid or
recombinant RhCMV vector. Moreover, expression of this fusion protein is stable over multi-
ple passages of the RhCMVgagfliCΔ196–378 in cell culture.
The use of RhCMV as a lentiviral vaccine vector has been recently reviewed [27]. RhCMV
vectors have demonstrated significant protection from disease progression in the macaque
model of AIDS, with 50% of vaccinated animals able to control SIV replication after a mucosal
challenge with pathogenic SIVmac239 [9, 10]. While RhCMV encodes numerous immune
modulators, the inclusion of flagellin as a TLR5 agonist is unique. Human CMV [28] and
RhCMV [29] encode an IL-10 homolog that reduces inflammatory responses at the site of
inoculation [24]. Paradoxically, CMV can also induce proinflammatory cytokines and chemo-
kines in infected monocytes and macrophages, including TNF-α [30–32]. A recent study dem-
onstrated that infection of monocyte-derived macrophages with a low-passage clinical strain of
HCMV resulted in the upregulation of several TLRs, including TLR5, and expression of NF-κB
via the MyD88 signaling pathway [30]. Interestingly, that study also demonstrated that while
infection of macrophages with HCMV induced the upregulation of TNF-αmRNA, treatment
with lipopolysaccharide (LPS) was required for induction of TNF-α protein expression [30].
Another study utilizing a HCMV clinical isolate demonstrated that early in infection, HCMV
down-regulates the TNF-α receptor [33], perhaps as a means to modulate TNF-α responses in
order to tip the host-microbe balance in favor of infection. The long-term consequences of
encoding a TLR5 agonist as an adjuvant within a high-passage fibroblast adapted RhCMV
clone remain to be determined in ongoing experimental studies in rhesus macaques. However,
our data clearly demonstrate that RhCMVgagfliCΔ196–378 replicates in cell culture with stable
expression of the Gag-FliC fusion protein and also induces TNF-α in a TLR5-specific manner.
The use of FliC as an adjuvant for an HIV-1 vaccine has been previously described [34, 35].
One study utilized recombinant baculovirus to generate chimeric HIV virus-like particles con-
taining membrane-bound HIV Envelope and HV domain-truncated FliC [34]. Enhanced sys-
temic and mucosal immune responses in guinea pigs demonstrated the feasibility of FliC as an
adjuvant for improving HIV-1 immune responses [34]. Another study utilized plasmid-
encoded FliC fused to interleukin-18 as an adjuvant for SIV Gag, which was encoded on a sepa-
rate plasmid [35]. BALB/C mice immunized with these plasmid vectors developed stronger
immune responses to SIV Gag than animals vaccinated with plasmids encoding either IL-18 or
FliC alone or delivered concomitantly [35]. However, these previous studies did not utilize a
replicating vector.
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This current study describes the construction and characterization of a novel replicating,
RhCMV vector-based vaccine that expresses SIV antigen fused to a TLR5 ligand. The results
described here demonstrate that the virus serves its function to induce TNF-α via TLR5. Exper-
iments designed to determine whether this enhanced innate signaling will result in a more
immunogenic and efficacious vaccine are ongoing and critical for evaluation of this type of
adjuvant approach for an RhCMV-vectored SIV vaccine.
Materials and Methods
Experimental Animals and Infection
For the entirety of this study, 35 female rhesus macaques (Macaca mulatta; Mmu) were used
from the retrovirus-free colony of the California National Primate Research Center (CNPRC)
at the University of California (UC) at Davis. This study was approved by the UC Davis Institu-
tional Animal Care and Use Committee (IACUC; approval number: 17880). UC Davis has an
Animal Welfare Assurance on file with the NIH Office of Laboratory Animal Welfare
(OLAW), and is fully accredited by the Association for the Assessment and Accreditation of
Laboratory Animal Care, International (AAALAC). Animals were administered 10 mg/kg
body weight ketamine-HCl (Parke-Davis, Morris Plains, NJ, USA) intramuscularly when nec-
essary for immobilization. Additionally, analgesics were administered at the discretion of the
CNPRC veterinary staff in an effort to minimize pain and discomfort. Animals were main-
tained at the CNRPC in cages with 4 square feet of floor space, or 6 square feet if over 10 kg,
with fixed perch bars in a temperature-controlled BSL-2+ vivarium with continuous monitor-
ing of temperature and humidity. Compatible animals were paired continuously or intermit-
tently (separated at night) whenever possible. All animals had visual and auditory access to
other macaques 24 hours per day. These animals were fed a balanced commercial macaque
chow (Purina Mills, Gray Summit, MO) twice daily and fresh produce twice weekly, with free
access to water 24 hours per day. Supplemental food was provided when clinically indicated.
Environmental enrichment was provided daily, including manipulanda (forage boards, mir-
rors, puzzle feeders) and novel foodstuffs. All animals are involved in ongoing studies designed
to determine vaccine efficacy and remain housed as described.
Each macaque was inoculated subcutaneously (SC) in the back with 1x104 plaque forming
units of either: RhCMV (68–1), RhCMVgag, or RhCMVgagfliCΔ196–378. Skin biopsies were
taken one week post-inoculation and the animals were returned to their housing.
Construction of FliC Expression Vectors
Full-length FliC expression vector. Plasmid pET29aflagellin encoding Salmonella enterica
serovar Enteritidis FliC (flagellin) (kindly provided by S. Mizel; Wake Forest University) was
used to construct a flagellin eukaryotic expression vector [36]. fliC was cloned into the eukary-
otic expression plasmid pSV40EC1-72, generating plasmid pSV40fliC using standard molecu-
lar biology techniques. Plasmid clones were submitted to UC Davis Sequencing for
verification. Plasmid pORI, containing an R6K origin of replication, was acquired from Louis
Picker (Oregon Health Sciences University). fliC from pSV40fliC was cloned into pORI using
standard molecular biology techniques, generating plasmid pORIfliC. Plasmid clones were
propagated in E. coli DH5α-λpir+ and submitted to UC Davis Sequencing for verification.
FliC hypervariable region mutant expression vectors. Overlap-extension PCR [37] was
used to truncate the hypervariable (HV) domain of FliC. To generate FliCΔ196–378, nucleo-
tides 586 to 1134 encoding amino acids 196 to 378 were deleted (GenBank: AY353386) [14]. A
second FliC HV region truncation mutant was generated by deleting nucleotides 424 to 1194
encoding amino acids 141 to 398 generating FliCΔ141–398. Primers for the first round PCR
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amplification of fliCΔ196–378 construct were WLC81 and JDD4 for nucleotides 1 through 423
and JDD3 and WLC82 for nucleotides 1135 through 1518 (Table 1). Primers for the first
round PCR amplification of the fliCΔ141–398 construct were WLC81 and JDD4 for nucleo-
tides 1 through 423 and JDD3 andWLC82 for nucleotides 1135 through 1518 (Table 1).
Round two PCR was performed using round one PCR products as template and primers
WLC81 and WLC82 (Table 1). Round two PCR products were cloned into the AgeI and NotI
REase sites of the eukaryotic expression plasmid pSV40EC1-72, generating plasmids
pSV40fliCΔ196–378 and pSV40fliCΔ141–398. fliCΔ196–378 and fliCΔ141–398 were subse-
quently cloned into the BamHI and SalI REase sites of plasmid pORI, generating pORI-
fliCΔ196–378 and pORIfliCΔ141–398. Plasmid clones were propagated in E. coliDH5α-λpir
+ and submitted to UC Davis Sequencing for verification.
SIV Gag-FliC fusion protein expression vectors. To generate an SIV Gag-FliC fusion
protein expression vector, fliC was PCR amplified from pET29aflagellin using primers JDD9
and JDD10 (Table 1) as described above. These primers were designed to delete the Kozak
sequence and the start codon as well as to introduce a novel AgeI REase site at the 5’ end and a
novel SalI REase site at the 3’ end of fliC. The final PCR product was cloned into
pCR2.1-TOPO (Invitrogen), generating the plasmid pCR2.1fliC(ΔATG). fliCΔ196–378 was
also prepared for construction of an SIV Gag fusion protein using overlap-extension PCR as
described above to truncate the hypervariable region of FliC, delete the Kozak sequence and
the start codon, and to introduce AgeI and SalI REase sites. The first round primer pairs were
JDD9/JDD4 and JDD3/JDD10 (Table 1). The second round primers were JDD9 and JDD10
(Table 1). The final PCR product was cloned into pCR2.1-TOPO (Invitrogen), generating
p2.1fliCΔ196-378(ΔATG). The plasmid pORIgag, encoding a codon-optimized SIVmac239
Gag, was acquired from Louis Picker (OHSU). SIVgag was PCR amplified using primers JDD7
and JDD8 (Table 1). The primers were designed to introduce a novel NheI REase site upstream
of SIVgag, a novel AgeI REase site at the 3’ end, and to remove the downstream flag tag and
stop codon. The PCR product was cloned into pCR2.1-TOPO (Invitrogen) to generate
pCR2.1gag. Due to SIVgag subcloning orientation problems, possibly resulting from bacterial
selection due to read-through from the lacZ gene of pCR2.1-TOPO, fliC(ΔATG) and fliCΔ196-
378(ΔATG) were cloned into the EcoRI and SalI REase sites of pUC19, generating the plasmids
pUC19fliC(ΔATG) and pUC19fliCΔ196-378(ΔATG). Next, SIVgag from pCR2.1gag was
cloned into the EcoRI and AgeI REase sites of the pUC19fliC vectors, generating the plasmids
pUC19gagfliC and pUC19gagfliCΔ196–378. gagfliC and gagfliCΔ196–378 were then cloned












*All sequences are written 5’ to 3’
doi:10.1371/journal.pone.0155629.t001
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into the NheI and SalI REase sites of the pORI expression vector, generating plasmids pORI-
gagfliC and pORIgagfliCΔ196–378. These plasmids encoded a SIVgag gene separated from fliC
by a single AgeI REase site, a single Kozak sequence and start codon at the start of SIVgag, and
a single stop codon at the 3’ end of fliC. The plasmids were propagated in E. coli DH5α-λpir
+ and submitted to UC Davis Sequencing for verification.
FliC TLR5 Functional Assay
The TLR5-specific functional activity of FliC, FliCΔ196–378, and FliCΔ141–398 expression
plasmids were tested by measuring TNF-α production in vitro using an ELISA as previously
described [14]. Telomerized rhesus fibroblast cells (TeloRFs) [38] were seeded at 5 x 105 cells
per well 2 ml of DMEM supplemented with 10% Fetal Bovine Serum (FBS) and 1X penicillin
plus streptomycin in 6-well tissue culture plates and incubated overnight at 37°C. The TeloRFs
were then transfected with pORIfliC, pORIfliCΔ196–378, or pORIfliCΔ141–398 using
FuGENE6 transfection reagent (Promega) according to the user’s manual and returned to the
37°C incubator. The transiently transfected TeloRFs were collected by removing growth media,
washing the cells once with 1X phosphate buffered saline (PBS), adding 500 μl of growth media,
lifting the cells from the tissue culture well with a rubber cell scraper and were then transferred
to 1.5 ml centrifuge tubes. Lysates were generated from freezing the cell suspensions at -80°C,
thawing in a water bath at 37°C, and repeating for a total of three freeze/thaw cycles. Lysates
were then repeatedly passed through a 22-gauge needle attached to a 1 ml syringe and stored at
-20°C. Recombinant FliC and the mouse macrophage cell lines RAW264.7 (TLR5 negative) and
RAW424 (TLR5 positive) [39] were acquired from Steven Mizel (Wake Forest University) and
used to test the lysates from FliC-transfected TeloRFs for TLR5 activity as previously described
[14]. Briefly, 4 x 105 RAW264.7 cells and 5 x 105 RAW424 cells were seeded in 1 ml of growth
media per well in 24-well plates and incubated at 37°C overnight in a humidified CO2 incuba-
tor. The cells were then treated with 20 μl of lysate from TeloRFs or with recombinant FliC for
four hours at 37°C. Cell culture supernatant was collected and stored at -20°C until analysis for
TNF-α content by ELISA (UCytech) according to the manufacturer’s instructions. Preliminary
experiments demonstrated maximal TNF-α production on RAW424 cells with treatment of
FliC-transfected TeloRF lysates collected between 24 and 48 hours post-transfection; the
48-hour time point was subsequently used throughout the remainder of the study.
RhCMV Expressing SIVgagfliCΔ196–378
To generate a recombinant RhCMV that expresses the SIVgagfliCΔ196–378 fusion protein,
Red/ET recombination (Gene Bridges) [40] was used as previously described [8] to insert SIV-
gagfliCΔ196–378 from the plasmid pORIgagfliCΔ196–378 into the non-coding region between
rh213 and rh214 of a bacterial artificial chromosome (BAC) containing a complete molecular
clone of the RhCMV 68–1 genome, RhCMV-loxP(r) [23]. Briefly, a culture of DH10B E. coli
carrying RhCMV-loxP(r) encoding chloramphenicol (Cam) resistance and plasmid
pSC101-BAD-gbaA containing a temperature sensitive origin of replication and encoding tet-
racycline (Tet) resistance [40] was propagated overnight at 30°C in LB broth containing Cam
(25 μg/ml) and Tet (3 μg/ml). The overnight stationary culture containing selective antibiotics
was propagated at 30°C until an optical density at 600 nm of 0.2. L-arabinose was added to
0.2% to induce expression of the recombinases, and the cells were propagated at 37°C until an
optical density at 600 nm of 0.3–0.4. A PCR product containing the EF1-α promoter, SIVgag-
fliCΔ196–378, and a kanamycin (Kan) resistance cassette was generated from the PCR amplifi-
cation of pORIgagfliCΔ196–378 with Advantage 2 DNA polymerase (Clonetech) using primers
WLC87 (5’ GGGAAATCACGTCATCAGGCTGGGTAGTCAACATGGGCATACGAAACTTGCCCG
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AATAGATGCTCTCACTTAACGGCTGACATG 3’) and WLC88 (CCAGAATGTGCTCTAC
TTTTTGGCCAGCGGGTTGGATGATTTCGCGCGTCATGGACTGCTTCACTGTAGCTTAG
TACGTTAAAC). The purified PCR product was transformed into the recombination-ready
electrocompetent DH10B E. coli using electroporation in a Gene Pulser (BioRad) and trans-
formed cells were recovered in SOC media for 2–3 hours at 37°C, plated on LB agar containing
Cam (25 μg/ml) and Kan (30 μg/ml) and incubated overnight at 37°C. Single colonies were
selected and grown overnight in LB broth containing Cam and Kan at 37°C. BAC DNA was
isolated from the cultures using the Boil Prep Procedure and precipitation in isopropanol. The
purified BAC DNA was then screened by PCR for the presence of the EF1-α promoter-SIVgag-
fliCΔ196-378-Kan resistance cassette insert in between the Rh213 and 214 region of the
RhCMV genome using primers JDD19 and JDD8 specific for Rh213 and SIVgag, respectively,
and primers JDD9 and JDD20, specific for fliC and Rh214. Clones were selected and propa-
gated in LB broth containing Cam (25 μg/ml) and Kan (30 μg/ml). Cells were transformed
with pCP20, containing a temperature-sensitive origin of replication and expressing flp recom-
binase and a bla antibiotic resistance gene, by electroporation. After recovery, cells were plated
on LB agar plates containing Cam (25 μg/ml) and Amp (50 μg/ml) and incubated overnight at
30°C. Selected colonies were streaked onto LB agar plates containing Cam (25 μg/ml) and incu-
bated overnight at 43°C to induce flp recombinase. Colonies were selected from the 43°C plates
and screened for Amp and Kan sensitivity. Selected clones were propagated in LB broth con-
taining Cam (25 μg/ml) and BAC DNA was isolated using the boil prep method. Purified BAC
DNA was analyzed by PCR for presence of the EF1-α promoter-SIVgagfliCΔ196–378 insert in
between Rh213 and Rh214 of the RhCMV genome in addition to the absence of the Kan resis-
tance gene using primer pairs JDD19/JDD8 and JDD9/JDD20 as described above. Positive
clones were selected, and BAC DNA was purified using a NucleoBond BACMaxi kit (BD Bio-
sciences) according to user’s manual.
The accuracy of the insert was further confirmed through a primer walking and Sanger
sequencing strategy. The entire region of approximately six kilobases was PCR amplified with
primer pair prRh90-F/prRh90-R and the amplicon was Sanger sequenced with the primers
listed in Table 2. The sequence and stability of the insert was also investigated with high
throughput sequencing of the purified BAC on the ION Torrent platform, either by direct
sequencing or PCR amplifying the entire construct. Library preparation, sequencing and analy-
sis were performed as described previously [41]. High throughput sequencing of the construct
directly or after PCR amplification resulted in near 100% coverage of the RhCMV genome
with low error rates (S1 Fig). The insert sequence was highly stable in the sequenced pool of
BAC constructs, with no evidence of low frequency insertions or deletions within the region.
TeloRFs were transfected with BAC DNA using FuGENE (Roche) according to the user’s
manual and were maintained in culture until apparent cytopathic effect. Cell culture superna-
tant was collected and used to infect fresh TeloRFs. Virus that was serially passed through
three passages was expanded in TeloRFs, purified and stored in liquid nitrogen vapor as previ-
ously described [23]. Lysates generated from TeloRF cell pellets during serial passage were
tested for FliC TLR5 functional activity as described above.
Western Blot Analysis
For SIV GagWestern blot analysis, TeloRF cell lysates were separated by SDS-PAGE and trans-
ferred to polyvinylidene fluoride (PVDF) transfer membranes (Amersham) using standard lab-
oratory procedures. The membranes were blocked for nonspecific protein binding overnight at
room temperature in 5% skim milk and 0.1% Tween20 in PBS and then probed using SIV Gag
p27 monoclonal antibody [42]. An anti-mouse IgG peroxidase conjugated antibody (Sigma
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clone: A5906) and 3,3’-diaminobenzidine (DAB; Vector Laboratories) were used for immuno-
detection. Western blot analysis for β-Actin (C4) (Santa Cruz Biotechnology; sc-47778 HRP)
was also performed on the TeloRF cell lysates according to the manufacturer’s instructions.
Histopathology
Prior to the collection of biopsies, animals were sedated with Ketamine and 0.2 mL of Lido-
caine was administered to the biopsy site to minimize discomfort according to an IACUC-
approved protocol (FF-1). The biopsy site was shaved and the area was cleansed using betadine
scrub solution, alcohol, and betadine prep solution by a sterile saline rinse. Biopsies were
obtained using a sterile, six mm punch type biopsy tool with the help of a sterile scalpel blade if
needed. Post-exposure analgesics were administered according to an IACUC-approved proto-
col (LL-5). Biopsies were fixed in neutral buffered formalin, and processed by routine histology
technique. Sections were stained with hematoxylin and eosin, coded with random numbers,
and then blindly examined by a board-certified veterinary pathologist (SWB).
Although the biopsies all represented areas of inoculation, the depth of the inoculation was
variable, ranging from dermis to subcutis and panniculus carnosis. Some of the samples did not
contain all tissue layers. The nature of the inflammation was similar among all positive samples,
but was multifocal and varied in location and depth within the sample. Therefore, it was not pos-
sible to comparatively score the samples by cell count or other objective criteria. They were there-
fore scored on an overall scale of 0 (no inflammation present) to 3 (severe inflammation).
Inflammation was independently scored for the dermis, subdermis, and subcutis/panniculus car-
nosis, and the overall highest score was used for comparison among samples (S2–S5 Figs). Mild
inflammatory changes (1+) consisted of focal perivascular infiltrates of lymphocytes, plasma
cells, few polymorphonuclear cells, and macrophages, some of which were enlarged (cytomegaly)
and contained intranuclear viral inclusion bodies. Moderate inflammatory changes (2+) con-
sisted of multifocal areas of similar cellular infiltrates with evidence of vascular hyperemia, and
edema. Severe lesions (3+) had intense multifocal and often coalescing areas of leukocyte infiltra-
tion and hemorrhage with numerous cytomegalic macrophages with intranuclear viral inclusion
bodies. Focal acute hemorrhage, associated with surgical excision, was present in most biopsies.
Supporting Information
S1 Fig. Cumulative error probability from RhCMV BAC resequencing data. The entire
RhCMV BAC was either directly sequenced (red) or sequenced after PCR amplification (blue).
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Polymorphisms within the data were assumed to be sequencing errors, allowing for estimation
of error rates. The cumulative error probability from these data was then plotted.
(PDF)
S2 Fig. Representative Image of Inflammatory Score 0. This is a representative image of a
skin biopsy corresponding to an inflammatory score of 0 (no inflammation present).
(TIF)
S3 Fig. Representative Image of Inflammatory Score 1. This is a representative image of a
skin biopsy corresponding to an inflammatory score of 1 (mild inflammation present).
(TIF)
S4 Fig. Representative Image of Inflammatory Score 2. This is a representative image of a
skin biopsy corresponding to an inflammatory score of 2 (moderate inflammation present).
(TIF)
S5 Fig. Representative Image of Inflammatory Score 3. This is a representative image of a
skin biopsy corresponding to an inflammatory score of 3 (severe inflammation present).
(TIF)
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